Cystitis, Interstitial Clinical Trial
Official title:
Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis
A Randomized, Double-blind, Placebo Controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome
Interstitial cystitis (IC) is a chronic disabling bladder syndrome characterized by urinary frequency, nocturia, urinary urgency, and pain or discomfort with bladder filling. There is no cure for IC and the treatment options are suboptimal. Patients with IC report significant negative effects on their physical and mental quality of life. The etiology of IC is unknown. Certain aspects of IC suggest that autoimmunity may play a role in initiating or sustaining the chronic inflammatory response. Bladder biopsies of patients with IC demonstrate an increase number of mast cells. Mast cell activation with the release of tumor necrosis factor (TNF) may mediate this bladder inflammation. Cimzia (certolizumab pegol) is a medication that blocks the effect of TNF. Cimzia (certolizumab pegol) is FDA approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. These diseases are similar to IC. In this study, the hypothesis being tested is that Cimzia (certolizumab pegol) will show efficacy in improving the symptoms of patients with IC. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02868775 -
A Study to Determine the Role of Toll-like Receptor-4 Expression in Patients With Interstitial Cystitis/Bladder Pain Syndrome
|
N/A | |
| Completed |
NCT00672087 -
Diagnostic Challenges in IC (and Male CPPS)
|
||
| Completed |
NCT01482676 -
The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction
|
N/A | |
| Terminated |
NCT00380783 -
Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis
|
Phase 2 | |
| Completed |
NCT00775281 -
Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC.
|
N/A | |
| Completed |
NCT05260112 -
Smartphone-based Self-care Education Program for Women With Interstitial Cystitis: Educational Remote IC Aide
|
N/A | |
| Completed |
NCT05752344 -
Interstitial Cystitis: Monitoring of the Psychic State and Counseling Intervention in the COVID-19 Era
|
||
| Completed |
NCT01613586 -
A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)
|
Phase 2 | |
| Completed |
NCT02411110 -
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
| Recruiting |
NCT06299683 -
Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment
|
N/A | |
| Completed |
NCT00248664 -
Events Preceding Interstitial Cystitis (EPIC)
|
N/A | |
| Completed |
NCT00601484 -
An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis
|
Phase 2 | |
| Completed |
NCT02214550 -
Chronic Pain Risk Associated With Menstrual Period Pain
|
Phase 4 | |
| Completed |
NCT04275297 -
Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome
|
N/A | |
| Terminated |
NCT00999518 -
A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
|
Phase 2 | |
| Completed |
NCT00675298 -
Linkage Analysis in Interstitial Cystitis
|
N/A | |
| Terminated |
NCT02781103 -
Guided Imagery and Transcranial Direct Current Stimulation (tDCS) in Women With Chronic Pelvic Pain
|
N/A | |
| Recruiting |
NCT01074567 -
DMSO Efficacy in IC/PBS Patients During and After Treatment
|
N/A | |
| Terminated |
NCT02787083 -
A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis
|
Phase 3 | |
| Withdrawn |
NCT00275379 -
Study Evaluating Orally Administered ERB-041 in Subjects With Active Interstitial Cystitis
|
N/A |